🔍
A Combination of Carbapenem and Avibactam for Treatment of Bacterial Infections
Case ID:
C14548
Report of Invention:
1/20/2017
Web Published:
2/5/2018
UNMET NEED
Multidrug-resistant (MDR) pathogens, e.g.
M
ycobacterium
tuberculosis
(TB) are a growing threat with significant economic ramifications. In particular, TB is one of the top 10 causes of death worldwide, with an estimated 10.4 million people infected, globally. An estimated 1.8 million deaths are attributable to TB. MDR-TB is TB that does not respond to the 2 most powerful anti-TB drugs, and approximately 500,000 people developed MDR-TB in 2015. Globally, only 52% of MDR-TB patients are successfully treated, demanding new approaches to combating this pathogen. This specific case is part of a larger and growing trend of antibiotic resistance that will require new combative strategies. One such strategy is combining common antibiotics with additional compounds that increase and/or restore the susceptibility of resistant bacteria to current therapeutics. Without a way to restore this susceptibility, the minimum inhibitory concentrations (MICs) for carbapenems to successfully treat MDR pathogens are neither safe nor tolerated in infected individuals. This invention provides a way to begin developing such a restorative regimen.
TECHNOLOGY OVERVIEW
The inventors have found that a combination of the carbapenem class of antibiotics and avibactam (a beta-lactamase inhibitor) IS POTENT AGAINST
Mycobacterium
absessus
and potentially against other patohogenic bacteria. This discovery presents a unique opportunity to develop a regimen to treat MDR bacterial infections. Notably, a combination of tebipenem, ertapenem, or panipenem with avibactam presented the greatest shift in MIC, indicating that Avibactam restores MICs of carbapenem-class antibiotics against
M.
abscessus
to therapeutically achievable concentrations of the drugs.
STAGE OF DEVELOPMENT
•Preclinical
ASSOCIATED PUBLICATIONS
■
Kaushik, A, et al. Future Micro. 12.6. 2017
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
A Combination of Carbapenem and Avibactam for Treatment of Bacterial Infections
ORD: Ordinary Utility
United States
15/877,762
10,434,089
1/23/2018
10/8/2019
1/25/2038
Granted
AVIBACTAM AND CARBAPENEMS ANTIBACTERIAL AGENTS
CON: Continuation
United States
16/560,006
10,842,783
9/4/2019
11/24/2020
1/23/2038
Granted
Direct Link:
https://jhu.technologypublisher.com/technology/27063
Inventors:
Category(s):
Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Sahil Aggarwal
sahil.aggarwal@jhu.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum